|Bid||4,477.90 x 0|
|Ask||4,482.00 x 0|
|Day's Range||4,200.00 - 4,585.40|
|52 Week Range||3,588.15 - 5,875.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||39.40|
|Earnings Date||Nov 14, 2020 - Nov 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3,031.50|
Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run. In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany's BioNTech SE, is safe and effective. If the vaccine is shown to work by then, Pfizer has said it would quickly seek regulatory approval.
News of serious side effects in one participant of AstraZeneca's COVID-19 vaccine trial led some volunteers in Johnson & Johnson's vaccine trial in Spain to drop out, its lead investigator told Reuters on Tuesday. "Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions," Borobia said in the interview.
India's top pharmaceuticals export group said the government's curbs on some drug exports amid the spreading coronavirus outbreak has caused panic in Europe and will "severely impact" businesses in the sector. India, the world's main supplier of generic drugs, has restricted the export of 26 active pharmaceutical ingredients (APIs) and the medicines made from them, in a move seen aimed at tackling possible domestic shortages of medicine during the outbreak. On Wednesday, Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), told Reuters that some of the restricted APIs and medicines were widely exported to Europe and the United States.